LABIANA HEALTH S.A.EO-10 Market Cap ($48.63 Million)
Market Cap & Net Worth: LABIANA HEALTH S.A.EO-10 (8RK)
LABIANA HEALTH S.A.EO-10 market cap. LABIANA HEALTH S.A.EO-10 (F:8RK) has a market capitalization of $48.63 Million (€41.60 Million) as of November 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #21832 globally and #1936 in its home market, demonstrating a 1.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LABIANA HEALTH S.A.EO-10's stock price €4.90 by its total outstanding shares 8489255 (8.49 Million). Also see cash flow conversion of LABIANA HEALTH S.A.EO-10 for how efficiently the company converts equity into cash flow.
LABIANA HEALTH S.A.EO-10 Market Cap History (2022–2026)
LABIANA HEALTH S.A.EO-10 market cap history from 2022 to 2026. Data shows growth from $30.17 Million to $48.63 Million (18.44% CAGR). Check today's stock price for LABIANA HEALTH S.A.EO-10 for real-time trading data and today's change.
LABIANA HEALTH S.A.EO-10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LABIANA HEALTH S.A.EO-10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore LABIANA HEALTH S.A.EO-10 (8RK) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.58x
LABIANA HEALTH S.A.EO-10's market cap is 0.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
16.92x
LABIANA HEALTH S.A.EO-10's market cap is 16.92 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $30.17 Million | $57.85 Million | -$8.94 Million | 0.52x | N/A |
| 2023 | $11.71 Million | $58.46 Million | -$4.42 Million | 0.20x | N/A |
| 2024 | $26.80 Million | $66.26 Million | $253.45K | 0.40x | 105.73x |
| 2025 | $43.47 Million | $75.18 Million | $2.57 Million | 0.58x | 16.92x |
Competitor Companies of 8RK by Market Capitalization
Companies near LABIANA HEALTH S.A.EO-10 in the global market cap rankings as of November 3, 2026. Also see LABIANA HEALTH S.A.EO-10 asset portfolio for a full breakdown of the balance sheet.
Key companies related to LABIANA HEALTH S.A.EO-10 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of LABIANA HEALTH S.A.EO-10 (2022–2026)
Market capitalization of LABIANA HEALTH S.A.EO-10 from 2022 to today. Between 2022 and today, LABIANA HEALTH S.A.EO-10's market cap moved from $30.17 Million to $ 48.63 Million, with a yearly change of 18.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €48.63 Million | +11.87% |
| 2025 | €43.47 Million | +62.22% |
| 2024 | €26.80 Million | +128.81% |
| 2023 | €11.71 Million | -61.18% |
| 2022 | €30.17 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of LABIANA HEALTH S.A.EO-10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.63 Million USD |
| MoneyControl | $48.63 Million USD |
| MarketWatch | $48.63 Million USD |
| marketcap.company | $48.63 Million USD |
| Reuters | $48.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, North America, and internationally. It offers anesthetics-sedatives, anti-infectives, anti-inflammatories, antiparasitics, hormonals, nutritional products, metabolism regulators, and vitamin products. The company also provides sterile and lyophilized dosage f… Read more